Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs iShares MSCI India ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while iShares MSCI India ETF trades at $50.06. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| BIO | INDA | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $356.25 | $55.29 |
52-Week Low | $241.71 | $45.42 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INDA, trading at $50.39 with a 0.54% daily gain, shows a bullish technical outlook supported by moving averages, though RSI levels indicate potential overbought conditions near-term. The ETF tracks India's equity market, the world's fastest-growing large economy, which expanded 7.8% in Q1 2026 (CNBC, June 5, 2026). Recent news highlights foreign capital rotation away from AI-heavy Asian markets, with India facing sector-specific headwinds in pharmaceuticals and IT.
The outlook remains positive given India's robust economic growth, but risks include U.S. tariff uncertainty, Middle East shipping disruptions impacting exports (Reuters, August 4, 2026), and El Niño monsoon concerns. Investor sentiment is mixed amid foreign outflows, yet structural growth opportunities support long-term potential. Key watchpoints are earnings delivery from underlying holdings and macroeconomic stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
